Key Takeaways
- Clinical Bottom Line
- What is GAVE Syndrome?
- Clinical Associations
- Endoscopic Diagnosis: The Watermelon Appearance
Clinical Bottom Line
| Feature | Diagnostic & Therapeutic Standard |
|---|---|
| Pathophysiology | Vascular ectasia in the gastric antrum; highly associated with systemic sclerosis and cirrhosis. |
| Endoscopic Appearance | Classic “Watermelon Stomach” (linear red stripes converging on the pylorus) or diffuse punctate lesions. |
| Clinical Presentation | Chronic, occult upper gastrointestinal bleeding leading to severe iron-deficiency anemia; rarely presents with acute hematemesis. |
| First-Line Therapy | Argon Plasma Coagulation (APC) via endoscopy to ablate the superficial vascular lesions. |
| Second-Line Therapy | Radiofrequency Ablation (RFA) for APC-refractory cases, or surgical antrectomy for intractable bleeding. |
What is GAVE Syndrome?
Gastric Antral Vascular Ectasia (GAVE), commonly known as “Watermelon Stomach,” is a rare but significant cause of chronic upper gastrointestinal bleeding. It accounts for up to 4% of non-variceal upper GI bleeds. The condition is characterized by the presence of dilated mucosal and submucosal blood vessels (ectasias), specifically localized to the gastric antrum.
Unlike peptic ulcer disease, which typically causes acute, overt bleeding, GAVE most frequently presents insidiously. Patients suffer from chronic, occult blood loss leading to severe, transfusion-dependent iron-deficiency anemia. Less commonly, patients may present with melena or hematemesis.
Clinical Associations
GAVE is rarely an isolated phenomenon. It is strongly correlated with severe underlying systemic diseases:
- Cirrhosis and Portal Hypertension: Approximately 30% of patients with GAVE have concurrent cirrhosis. Crucially, GAVE must be distinguished from Portal Hypertensive Gastropathy (PHG), as the treatments differ entirely.
- Autoimmune Disease: Systemic Sclerosis (Scleroderma) is heavily associated with GAVE, with the condition sometimes referred to as the “GI manifestation of scleroderma.”
- Chronic Renal Failure: Frequently found in patients on long-term hemodialysis.
Endoscopic Diagnosis: The Watermelon Appearance
The diagnosis is almost exclusively endoscopic. The classic presentation involves distinct longitudinal stripes of erythematous, vascular lesions converging from the proximal antrum down toward the pylorus—resembling the dark stripes on a watermelon. However, a “diffuse/punctate” pattern also exists, particularly in cirrhotic patients, where the ectasias present as scattered red spots throughout the antrum.
Unlike PHG, which typically affects the fundus and gastric body and presents as a “snake-skin” mosaic pattern, GAVE is strictly confined to the antrum and consists of actual vessel dilatation.
Modern Therapeutic Interventions
Because GAVE lesions are mucosal and submucosal, they are highly amenable to endoscopic thermal ablation therapies.
Argon Plasma Coagulation (APC)
APC remains the gold-standard first-line therapy. It utilizes ionized argon gas to deliver high-frequency, non-contact thermal energy to the mucosa, coagulating the vascular ectasias at a superficial depth (typically 1–3 mm). This shallow depth prevents the deep thermal injury and perforation risks associated with traditional contact lasers (like Nd:YAG). Most patients require 2 to 4 sessions to achieve adequate ablation and transfusion independence.
Radiofrequency Ablation (RFA)
For patients who are refractory to APC (failing to stop bleeding after multiple sessions), Endoscopic Radiofrequency Ablation (RFA) has emerged as a highly effective second-line therapy. Originally designed for treating Barrett’s Esophagus, specialized focal-RFA catheters can cover broader areas of the antrum with a uniform depth of ablation, often succeeding where APC fails.
Surgical Antrectomy
In the rare event that endoscopic ablation totally fails, and the patient remains dependent on life-sustaining blood transfusions, surgical removal of the affected antral tissue (antrectomy) is the definitive, curative treatment. However, owing to the significant comorbidities (cirrhosis, renal failure) typical in this demographic, surgery is considered a high-risk last resort.
Clinical guidelines summarized by the Gastroscholar Research Team. Last updated: April 16, 2026. This article is intended for gastroenterologists.
